摘要
目的:研究人脑胶质瘤中bcl-2蛋白表达强度与胶质瘤的临床病理分级及患者预后间的关系。方法:应用免疫组化技术检测58例脑胶质瘤患者手术切除标本中bcl-2蛋白表达强度、HE染色确定肿瘤病理分级、门诊及电话随访,掌握患者术后生存时间。结果:bcl-2蛋白表达强度与肿瘤病理分级相关(P<0.01)、与患者术后生存时间相关(P<0.01)。bcl-2蛋白表达愈强,胶质瘤临床病理分级愈高、患者术后生存时间也愈短。结论:bcl-2蛋白表达水平与胶质瘤恶性程度成正比、与胶质瘤患者术后生存时间成反比,是评价胶质瘤恶性程度和预后的客观指标之一。
Objective:To detect the relationship among bcl-2protein and the pathological grade of glioma cells and prognosis of glioma.Methods:Fifty-eight specimens of glioma were examined by immunohistochemical technology and HE staining.The pathological grade and levels of bcl-2protein of the glioma cells were detected.the survival time of glioma patient after oper-ation were ascertained by follow up in our outpatient clinic and/or by telephone.Degree of corre-lation among levels of the bcl-2protein,the pathological grade of glioma cells and the survival time of patients.with Glioma after operation was analyzed.Results:Postive rate of bcl-2protein was86.2%.Levels of bcl-2protein were varied with different pathological grade and survival time of glioma patients after operation,the difference being significant (P<0.01).Higher levels of bcl-2were expressied on the surface of glioma cells with lower differentiation and shorter survival time of patients after operation Conclusions:levels of bcl-2protein were associated with the pathological grade of glioma cells and the survival time of the glioma patients after operation.It may serve as a marker in the evaluation of the malignanacy and prognosis of glioma.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2003年第7期480-482,共3页
Chinese Journal of Clinical Oncology
基金
广东省医学科研基金资助(编号:A2002498)
